AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Immune check point blockade therapy has revolutionized the standard of cancer treatment and is credited with producing remarkable tumor remissions and increase in overall survival. This unprecedented clinical success however is feasible for a limited number of cancer patients due to resistance occur...
Main Authors: | Vasileios Atsaves, Vasiliki Leventaki, George Z. Rassidakis, Francois X. Claret |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/7/1037 |
Similar Items
-
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01) -
Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
by: Qi X, et al.
Published: (2017-12-01)